Epilepsy and paroxysmal conditions

Advanced search

Metabolic disorders in patients with vestibular migraine

Full Text:


Objective: to assess vitamin D deficiency and hyperhomocysteinemia along with psychoemotional status in patients with vestibular migraine.

Material and methods. The neurovestibular examination of 23 patients was performed. All patients were diagnosed with vestibular migraine in accordance with the international criteria. The levels of 25-hydroxyvitamin D and homocysteine were assessed by enzyme-linked immunosorbent assay (ELISA). The effect of dizziness on everyday life was assessed according to the Dizziness Handicap Inventory (DHI). Psychoemotional status was investigated for all patients by using the following scales: Beck depression scale, Spilber–Hanin Scale, Toronto Alexithymia Scale (TAS-26).

Results. The mean level of 25-hydroxyvitamin D was 23±15 ng/ml, homocysteine – 11±3.4 μmol/L. The mean levels of situational and personal anxiety were 48.8±9 and 50.4±10.8, respectively. A correlation analysis revealed a significant positive correlation for Beck's depression parameters and DHI score (Spearman's criterion value 0.64, p=0.0016).

Conclusion. The data obtained evidence about a rather frequent detection of 25-hydroxyvitamin D insufficiency and deficit among patients with vestibular migraine that requires further evaluation, including expanding patients sample and/or comparison with other groups of patients. Of significance was to find an elevated level of anxiety and a correlation between the severity of dizziness (according to DHI score) and the level of depression (based on the Beck Scale).

About the Authors

A. S. Bedenko
Sechenov University
Russian Federation

Anna S. Bedenko – Postgraduate, Chair of Nervous Diseases and Neurosurgery

RSCI SPIN-code: 1533-6140

8 bld. 2 Trubetskaya Str., Moscow 119991

L. M. Antonenko
Sechenov University
Russian Federation

Lyudmila M. Antonenko – Dr. Med. Sc., Professor, Chair of Nervous Diseases and Neurosurgery

Scopus Author ID: 57220812877; RSCI SPIN-code: 2700-0886

8 bld. 2 Trubetskaya Str., Moscow 119991


1. Bronstein A.M., Lempert T. Dizziness: a practical approuch to diagnosis and managment. Cambrige University Press; 2007; 83–91.

2. Patel Z.S., Hoffman L.K., Buse D.C., et al. Pain, psychological comorbidities, disability, and impaired qualify of life in hidradenitis suppurativa. Curr Pain Headache Rep. 2017; 21 (12): 49.

3. Filatova E.G., Ivanova T.A. Diagnosis and principles of vertigo therapy in patients with migraine. Russian Medical Journal. 2018; 4 (2): 55–9.

4. Zhu C., Li Y., Ju Y., Zhao X. Dizziness handicap and anxiety depression among patients with benign paroxysmal positional vertigo and vestibular migraine. Medicine (Baltimore). 2020; 99 (52): e23752.

5. Gazquez I., Lopez-Escamez J.A. Genetics of recurrent vertigo and vestibular disorders. Curr Genomics. 2011; 12 (6): 443–50.

6. Neuhauser H.K., Radtke A. von Brevern M., et al. Migrainous vertigo: prevalence and impact on quality of life. Neurology. 2006; 67 (6): 1028–33.

7. Lempert T. Vestibular migraine. Semin Neurol. 2013; 33 (3): 212–8.

8. Gokdemir M.T., Nas C., Gokdemir G.S. Pentraxin 3 level in acute migraine attack with aura: patient management in the emergency department. Am J Emerg Med. 2020; 38 (1): 38–42.

9. Iljazi A., Ayata C., Ashina M., Hougaard A. The role of endothelin in the pathophysiology of migraine – a systematic review. Curr Pain Headache Rep. 2018; 22 (4): 27.

10. Tietjen G.E., Al Qasmi M.M., Athanas K., et al. Increasedvon Willebrand factor in migraine. Neurology. 2001; 57 (2): 334–6.

11. Pigarova E.A., Rozhinskaya L.Y., Belaya J.E., et al. Russian Association of Endocrinologists recommendations for diagnosis, treatment and prevention of vitamin D deficiency in adults. Problems of Endocrinology. 2016; 62 (4): 60–84 (in Russ.).

12. Diagnosis and treatment of balance disorders in diseases of the nervous system. Clinical guidelines. Мoscow; 2017. Available at: (in Russ.) (accessed 01.08.2021).

13. Kadykov A.S., Manvelova L.S. Tests and scales in neurology. Мoscow: MEDpress-inform; 2015: 224 pp. (in Russ.).

14. Starostina Е.G., Taylor G.D., Quilty L.K., et al. A new 20-item version of the toronto alexithymia scale: validation of the Russian language translation in a sample of medical patients. Available at: (in Russ.) (accessed 01.08.2021).

15. Casucci G., Villani V., Cologno D., D’Onofrio F. Migraine and metabolism. Neurol Sci. 2012; 33 (Suppl. 1): S81–5.

16. Togha M., Razeghi Jahromi S., Ghorbani Z., et al. Serum vitamin D status in a group of migraine patients compared with healthy controls: a case-control study. Headache. 2018; 58 (10): 1530–40.

17. Ivanova T.A., Filatova E.G. Vestibular migraine. Farmateka. 2015; 19: 21–7 (in Russ.).

18. Zandifar A., Masjedi S.S., Banihashemi M., et al. Vitamin D status in migraine patients: a case-control study. Biomed Res Int. 2014; 2014: 514782.

19. Rapisarda L., Mazza M.R., Tosto F., et al. Relationship between severity of migraine and vitamin D deficiency: a case-control study. Neurol Sci. 2018; 39 (Suppl. 1): 167–8.

20. Mottaghi T., Askari G., Khorvash F., Maracy M.R. Effect of vitamin D supplementation on symptoms and C-reactive protein in migraine patients. J Res Med Sci. 2015; 20 (5): 477–82.

21. Gazerani P., Fuglsang R., Pedersen J.G., et al. A randomized, double-blinded, placebo-controlled, parallel trial of vitamin D3 supplementation in adult patients with migraine. Curr Med Res Opin. 2019; 35 (4): 715–23.

22. Ghorbani Z., Rafiee P., Fotouhi A., et al. The effects of vitamin D supplementation on interictal serum levels of calcitonin gene-related peptide (CGRP) in episodic migraine patients: post hoc analysis of a randomized double-blind placebo-controlled trial. J Headache Pain. 2020; 21 (1): 22.

23. Ghorbani Z., Togha M., Rafiee P., et al. Vitamin D in migraine headache: a comprehensive review on literature. Neurol Sci. 2019; 40 (12): 2459–77.

24. Lippi G., Mattiuzzi C., Meschi T., et al. Homocysteine and migraine. A narrative review. Clin Chim Acta. 2014; 433: 5–11.

25. Cacciapuoti F. Migraine homocysteine-related: old and new mechanisms. Neurol Clin Neurosci. 2017; 5 (5): 137–40.

26. Bokhari F.A., Shakoori T.A., Hassan S.A., et al. Plasma homocysteine in patients of migraine without aura. J Ayub Med Coll Abbottabad. 2010; 22 (2): 52–5.

27. Isobe C., Terayama Y. Remarkable increase in total homocysteine concentrations in the CSF of migraine patients with aura. Headache. 2010; 50 (10): 1561–9.–4610.2010.01713.x.

28. Dresler T., Caratozzolo S., Guldolf K., et al. Understanding the nature of psychiatric comorbidity in migraine: a systematic review focused on interactions and treatment implications. J Headache Pain. 2019; 20 (1): 51.

29. Amoozegar F. Depression comorbidity in migraine. Int Rev Psychiatry. 2017; 29 (5): 504–15.

30. Kutay Ö., Akdal G., Keskinoğlu P., et al. Vestibular migraine patients are more anxious than migraine patients without vestibular symptoms. J Neurol. 2017; 264 (Suppl. 1): 37–41.


For citations:

Bedenko A.S., Antonenko L.M. Metabolic disorders in patients with vestibular migraine. Epilepsy and paroxysmal conditions. 2021;13(4):359-366. (In Russ.)

Views: 408

ISSN 2077-8333 (Print)
ISSN 2311-4088 (Online)